NO20043217L - Kombinert terapi mot tumorer omfattende substituerte acryloyl distamycin og protein kinase (serin/threonin kinase) inhibitorer - Google Patents

Kombinert terapi mot tumorer omfattende substituerte acryloyl distamycin og protein kinase (serin/threonin kinase) inhibitorer

Info

Publication number
NO20043217L
NO20043217L NO20043217A NO20043217A NO20043217L NO 20043217 L NO20043217 L NO 20043217L NO 20043217 A NO20043217 A NO 20043217A NO 20043217 A NO20043217 A NO 20043217A NO 20043217 L NO20043217 L NO 20043217L
Authority
NO
Norway
Prior art keywords
serine
inhibitors
acryloyl distamycin
kinase
combined therapy
Prior art date
Application number
NO20043217A
Other languages
English (en)
Inventor
Paolo Cozzi
Maria Cristina Rosa Geroni
Camilla Fowst
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20043217L publication Critical patent/NO20043217L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20043217A 2002-01-02 2004-07-29 Kombinert terapi mot tumorer omfattende substituerte acryloyl distamycin og protein kinase (serin/threonin kinase) inhibitorer NO20043217L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075052 2002-01-02
PCT/EP2002/013092 WO2003055522A1 (en) 2002-01-02 2002-12-18 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors

Publications (1)

Publication Number Publication Date
NO20043217L true NO20043217L (no) 2004-07-30

Family

ID=8185508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043217A NO20043217L (no) 2002-01-02 2004-07-29 Kombinert terapi mot tumorer omfattende substituerte acryloyl distamycin og protein kinase (serin/threonin kinase) inhibitorer

Country Status (24)

Country Link
US (1) US20060084612A1 (no)
EP (1) EP1461083B1 (no)
JP (1) JP2005516025A (no)
KR (1) KR20040078118A (no)
CN (1) CN1617744A (no)
AT (1) ATE321572T1 (no)
AU (1) AU2002352090B8 (no)
BR (1) BR0215454A (no)
CA (1) CA2472008C (no)
CY (1) CY1105269T1 (no)
DE (1) DE60210329T2 (no)
DK (1) DK1461083T3 (no)
ES (1) ES2263835T3 (no)
HU (1) HUP0402639A3 (no)
IL (2) IL162820A0 (no)
MX (1) MXPA04006543A (no)
NO (1) NO20043217L (no)
NZ (1) NZ533854A (no)
PL (1) PL371179A1 (no)
PT (1) PT1461083E (no)
RU (1) RU2328306C2 (no)
SI (1) SI1461083T1 (no)
WO (1) WO2003055522A1 (no)
ZA (1) ZA200405290B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
PT1545553E (pt) * 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
WO2006108763A1 (en) * 2005-04-08 2006-10-19 Nerviano Medical Sciences S.R.L. Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274576B1 (en) * 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors

Also Published As

Publication number Publication date
CN1617744A (zh) 2005-05-18
KR20040078118A (ko) 2004-09-08
RU2328306C2 (ru) 2008-07-10
WO2003055522A1 (en) 2003-07-10
DK1461083T3 (da) 2006-07-10
DE60210329D1 (de) 2006-05-18
RU2004123641A (ru) 2005-06-10
AU2002352090B8 (en) 2008-06-19
SI1461083T1 (sl) 2006-08-31
IL162820A (en) 2010-04-15
EP1461083B1 (en) 2006-03-29
HUP0402639A3 (en) 2012-02-28
ZA200405290B (en) 2005-06-17
PT1461083E (pt) 2006-08-31
CA2472008C (en) 2009-07-28
AU2002352090A1 (en) 2003-07-15
ES2263835T3 (es) 2006-12-16
DE60210329T2 (de) 2006-11-30
IL162820A0 (en) 2005-11-20
JP2005516025A (ja) 2005-06-02
MXPA04006543A (es) 2004-10-04
CY1105269T1 (el) 2010-03-03
BR0215454A (pt) 2004-11-23
US20060084612A1 (en) 2006-04-20
HUP0402639A2 (hu) 2005-04-28
EP1461083A1 (en) 2004-09-29
NZ533854A (en) 2007-05-31
PL371179A1 (en) 2005-06-13
AU2002352090B2 (en) 2008-05-15
ATE321572T1 (de) 2006-04-15
CA2472008A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
ATE297394T1 (de) Jun kinase inhibitoren
EA201000093A1 (ru) Производные пиридазинона
MY142045A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EA200901601A1 (ru) Производные пиридазинона
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
DK1292290T3 (da) Kombineret terapi mod tumorer omfattende substitueret acryloyl distamycinderivater og topoisomerase I og II inhibitorer
CY1105269T1 (el) Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης)
TW200503722A (en) Substituted 7-aza-quinazoline compounds
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
ATE388710T1 (de) Phthalazinderivate als phosphodiesterase-4-hemmer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application